Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al

D J McGrail¹, P G Pilié², N U Rashid³, L Voorwerk⁴, M Slagter⁵, M Kok⁶, E Jonasch², M Khasraw⁷, A B Heimberger⁸, N T Ueno⁹, R Ferrarotto¹⁰, J T Chang¹¹, S-Y Lin¹²

Affiliations

¹ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
² Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
⁴ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁵ Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
⁶ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁷ The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
⁸ Department of Neurological Surgery, Northwestern University, Chicago, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
⁹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹⁰ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹¹ Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹² Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.

PMID: 34166757
DOI: 10.1016/j.annonc.2021.06.017

Free article

Comment

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al

D J McGrail et al. Ann Oncol. 2021 Sep.

Free article

. 2021 Sep;32(9):1194-1197.

doi: 10.1016/j.annonc.2021.06.017. Epub 2021 Jun 21.

Authors

D J McGrail¹, P G Pilié², N U Rashid³, L Voorwerk⁴, M Slagter⁵, M Kok⁶, E Jonasch², M Khasraw⁷, A B Heimberger⁸, N T Ueno⁹, R Ferrarotto¹⁰, J T Chang¹¹, S-Y Lin¹²

Affiliations

¹ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
² Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
⁴ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁵ Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
⁶ Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁷ The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
⁸ Department of Neurological Surgery, Northwestern University, Chicago, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
⁹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹⁰ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹¹ Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹² Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.

PMID: 34166757
DOI: 10.1016/j.annonc.2021.06.017

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure MKh has served as a consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche and Jackson Laboratory for Genomic Medicine and received research funding from AbbVie, Bristol Myers Squibb (BMS) and Specialized Therapeutics. ABH has stock options and is an advisory board member of Caris Life Sciences, serves on the advisory board of WCG Oncology, has received licensing fees from Celldex Therapeutics and DNAtrix and received research funding from Merck. MKo has advisory roles for BMS, Roche, Merck Sharp & Dohme (MSD) and Daiichi Sankyo, and the institute receives research funding from AstraZeneca, BMS and Roche outside the submitted work. DJM, PGP, EJ and SYL have a pending patent on a gene expression signature to predict response to immune checkpoint blockade. All other authors have declared no conflicts of interest.

Comment on

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. McGrail DJ, et al. Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15. Ann Oncol. 2021. PMID: 33736924 Free PMC article.
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.
Fabrizio D, Cristescu R, Albacker L, Snyder A, Ward A, Lunceford J, Aurora-Garg D, Jin F, Hopkins J, Rubin E, Hegde P. Fabrizio D, et al. Ann Oncol. 2021 Sep;32(9):1193-1194. doi: 10.1016/j.annonc.2021.05.805. Epub 2021 May 31. Ann Oncol. 2021. PMID: 34082018 No abstract available.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

K99 CA240689/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al

Affiliations

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical